Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Allergy Therapeutics ( (GB:AGY) ) has provided an announcement.
Allergy Therapeutics has reported a financial turnaround with a 4% growth in half-year revenues and improvements in its cash position, indicating recovery and stability. The company has made significant strides in its allergy treatment programs, submitting a Marketing Authorisation Application for its Grass MATA MPL product and beginning a Phase III trial for pediatric patients. Encouraging interim data from its VLP Peanut PROTECT Trial shows potential efficacy in reducing skin sensitivity, supporting the transformative potential of its peanut allergy vaccine candidate.
More about Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company based in the UK, specializing in the treatment and diagnosis of allergic disorders. The company focuses on developing aluminium-free immunotherapy vaccines that can potentially cure diseases. It operates in nine major European countries and through distribution agreements in ten additional countries, offering a range of vaccines for allergens such as grass, tree, house dust mite, and peanut.
YTD Price Performance: 10.77%
Average Trading Volume: 502,085
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £343.2M
Find detailed analytics on AGY stock on TipRanks’ Stock Analysis page.
